EQT Life Sciences

EQT Life Sciences is delighted to announce that it has invested in Asceneuron SA’s oversubscribed Series C and Prof. Philip Scheltens will join the board of directors. Asceneuron SA – which is developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease – will use the funds to progress its lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease

EQT Life Sciences portfolio company Tubulis GmbH Receives FDA Fast Track Designation for Antibody-Drug Conjugate Candidate TUB-040 in Platinum-resistant Ovarian Cancer. An important step forwards for patients as OC is the leading cause of death among women diagnosed with gynaecological cancers, and nearly all patients who don't respond to platinum therapies will sooner or later develop resistance. Once resistant, outcomes are poor with a median survival of less than 16 months, leaving patients in desperate need of new treatment options. Read the full press release here: https://bit.ly/3RLXGNE

Don't miss our 2024 ThinQ Healthcare Dispatch. From its leading universities to innovation clusters, Europe has a healthcare success story to tell. Building on its scientific heritage, the region has created and nurtured companies worth billions of euros that have positively impacted the health of billions of people worldwide

We are pleased to announce that Cardior Pharmaceuticals, an EQT Life Sciences portfolio company, has today announced that it will be acquired by Novo Nordisk for up to EUR 1.025 billion. Cardior is a clinical-stage biotechnology company based in Hanover, Germany, developing RNA-targeted therapies for people with cardiovascular diseases. EQT Life Sciences led the company’s Series A financing in 2017 investing out of its LSP5 fund, with significant further investment in the Series B financing at the end of 2021. As Cardior’s largest shareholder, EQT Life Sciences played an important role in supporting the company’s development and the path towards advancing its novel therapy from preclinical experiments into clinical trials. Find out more about our journey supporting Cardior Pharmaceuticals here: EQT Life Sciences’ portfolio company Cardior Pharmaceuticals to be acquired by Novo Nordisk (eqtgroup.com)

We are pleased to announce that Cardior Pharmaceuticals, an EQT Life Sciences portfolio company, has today announced that it will be acquired by Novo Nordisk for up to EUR 1.025 billion. Cardior is a clinical-stage biotechnology company based in Hanover, Germany, developing RNA-targeted therapies for people with cardiovascular diseases. EQT Life Sciences led the company’s Series A financing in 2017 investing out of its LSP5 fund, with significant further investment in the Series B financing at the end of 2021. As Cardior’s largest shareholder, EQT Life Sciences played an important role in supporting the company’s development and the path towards advancing its novel therapy from preclinical experiments into clinical trials. Find out more about our journey supporting Cardior here:

On behalf of the entire EQT Life Sciences Dementia Fund Team, thank you for organizing this exciting event and inviting us. #adpd2024 Lisbon Great to see EQT Life Sciences Philip Scheltens together with Niranjan Bose, Susan Kohlhaas, Mark Roithmayr and Howard Fillit, MD, discussing the advancement of an increasingly rich pipeline of novel therapeutics to tackle hashtag #alzheimersdisease.

EQT Life Sciences is excited to lead a €128M Series B2 investment in Tubulis GmbH, a pioneering German biotech firm specializing in the development of novel antibody-drug conjugates (ADCs) for the treatment of solid tumors. This investment round, which is among the largest in the European healthcare sector this year, includes contributions from new US investors such as Nextech Invest (co-lead), Frazier Healthcare Partners, and Deep Track Capital. Overall, the financing will support Tubulis' vision to transform cancer treatment options through therapies that are both more effective and less harmful, enhancing patient survival and quality of life. Tubulis represents the type of innovative science-based companies we are committed to backing, aiming to deliver transformative and effective healthcare solutions. The collaboration with Bristol Myers Squibb underscores Tubulis' role at the forefront of scientific breakthroughs, reinforcing our dedication to supporting significant advancements in healthcare.| https://lnkd.in/eQhsGyMZ

We at EQT Life Sciences are looking for a new colleague - spread the word! Please apply via the below link.

We are pleased to announce that Amolyt Pharma , an EQT Life Sciences portfolio company, has today announced that it is to be acquired by AstraZeneca for up to USD 1.05 billion. Amolyt Pharma is a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. EQT Life Sciences originally invested in Amolyt’s Series A through its LSP 6 fund, as the lead investor. At the time the lead program was still in preclinical stages but with EQT’s support, the company has completed a phase I/II study and started a Phase III program, which is ongoing. Find out more about our journey supporting Amolyt Pharma here: https://lnkd.in/eZuh2rax

UK medtech startup Phagenesis Ltd Ltd has raised a $42m Series D to roll out its medical device for swallowing disorders in the US and expand its footprint in Europe. The round was co-led by Netherlands-based EQT Life Sciences and Canada-based Sectoral Asset Management Asset Management, British Patient Capital, Northern Gritstone and Aphelion also participated. https://lnkd.in/e4rvqBNX